Shulan Medical's Two Breakthrough Biomedical Therapies Approved for Clinical Use, Bringing World-Class Treatment to Chinese Patients Without Needing to Travel Abroad

Recently, Shulan (Boao) Hospital, under the Shulan Medical Group, announced major good news: two novel biomedical technologies—"Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Pulmonary Fibrosis" and "Activated T Lymphocyte Therapy for Preventing Postoperative Recurrence of Liver Cancer"—have been officially approved for clinical application. This breakthrough highlights the hospital’s core competitiveness in frontier technology research and development as well as clinical translation, enabling domestic patients with pulmonary fibrosis or those recovering from liver cancer surgery to access cutting-edge treatments on par with international standards without having to travel abroad.

As a pioneering medical institution rooted in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, Shulan (Boao) Hospital leverages the policy advantages of the pilot zone—such as “expedited introduction of approved drugs and medical devices” and “clinical application of novel biomedical technologies”—alongside the medical resource strengths of the Shulan Healthcare Group. The hospital focuses on addressing challenges in treating complex and refractory diseases, promoting the implementation and application of cutting-edge international medical technologies. The two cell therapy technologies recently approved were developed under the leadership of top-tier expert teams in China. Targeting two major clinical challenges—pulmonary fibrosis and postoperative recurrence of liver cancer—these technologies have undergone years of technical breakthroughs and rigorous clinical trials, ultimately achieving a critical transition from laboratory research to clinical application.

Pulmonary fibrosis, a refractory disease characterized by progressive fibrotic remodeling of the lung interstitium and destruction of alveolar structures, is often resistant to reversal by conventional therapies, posing severe challenges to patients’ quality of life and prognosis. The recently approved “Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Pulmonary Fibrosis” provides a novel therapeutic pathway for patients with chronic interstitial lung diseases.

As one of the most prevalent malignant tumors in China, hepatocellular carcinoma (HCC) has a postoperative five-year recurrence rate as high as 70%. The presence of preoperative micrometastases or multicentric lesions constitutes a key obstacle to long-term patient survival. Another approved technology, “Activated T-Lymphocyte Therapy for Preventing Postoperative Recurrence of Liver Cancer,” precisely addresses the core challenges in postoperative HCC management. By reducing the risk of recurrence at its source, this therapy provides a robust guarantee for achieving long-term tumor-free survival and cure in liver cancer patients.

The successful approval of two new biomedical technologies is a dual testament to Shulan (Boao) Hospital, part of Shulan Medical Group, and its commitment to the “patient-centered” philosophy and technological innovation capabilities. In recent years, the hospital has consistently focused on the introduction of specially permitted pharmaceuticals and medical devices, as well as the research, development, and innovative translation of cutting-edge medical technologies, establishing a full-chain service system spanning from R&D and clinical validation to practical application. Looking ahead, leveraging the group advantages and technological investment support of Shulan Medical, the hospital will continue to increase its investments in the biomedical field, constantly explore innovative treatment solutions for complex and refractory diseases, and accelerate the localization of more international frontier technologies and products in China. It aims to assist domestic innovative medical enterprises in rapidly bridging the gap between “scientific achievements and clinical applications,” accelerating technology implementation, enabling Chinese patients to access top-tier international medical services without leaving the country, and contributing greater “Shulan strength” to the Healthy China initiative.